STAT+: Pharmalittle: We’re reading about a Moderna Covid-flu vaccine, a paused Pfizer study, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: Pharmalot
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, the GSK-Elsie deal, and more
Good morning, Jason Mast here filling in for Ed. Today, we’re sipping a hot cup…
STAT+: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Student group that ranked med schools over industry conflicts votes to accept pharma funding
An organization devoted to educating future doctors about conflicts of interest will now accept industry…
STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits
Gilead Sciences agreed in principle to pay $40 million to more than 2,600 AIDS patients…
STAT+: U.S. drug shortages have reached a decade high and are lasting longer, too
Amid rising concern over prescription drug shortages, a new report finds that the number of…
STAT+: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility
A leading contract research organization has agreed to pay $35 million — including the largest-ever…
STAT+: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company…
STAT+: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows
Most physicians who endorsed a prescription drug or medical device on X — formerly known…
STAT+: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more
It’s an honor to fill in for Ed Silverman this morning. There is only one…
STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more
Top of the morning to you. I’m filling in for Ed Silverman this morning, which…
STAT+: Pharmalittle: We’re watching a ban compounded versions of GLP-1s, a Biogen acquisition, and more
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences…
.jpg)
STAT+: Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more
Good morning from the Pharmalittle campus, where I’m filling in for Ed. Normally, I’m the…
STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more
Good morning from STAT reporter Andrew Joseph, filling in here for Mr. Pharmalot. We’ve recently…
STAT+: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Roche obesity drug, an experimental Lilly insulin, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Getting abortion pills through the mail is safe, quick, and effective, study finds
Amid a national furor over access to abortion, a new study found that dispensing abortion…
STAT+: Pharmalittle: We’re reading about fake studies, AbbVie investing in psychedelics, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to…
STAT+: Pharmalittle: We’re reading about Pfizer’s DTC platform, Sandoz’s feud with a U.K. trade group, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Sandoz leaves U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis
In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group…
STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents
When it comes to a crucial controversy over pharmaceutical patents, the FDA has been MIA….
STAT+: Pharmalittle: We’re reading about Sanofi licensing Novavax’s Covid shot, Moderna’s RSV vaccine, and more
Hello there and happy Friday from STAT’s London outpost, where the weekend is mere hours…
STAT+: Pharmalittle: We’re reading about Takeda restructuring, Pfizer settling Zantac suits, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
In the latest bid to widen access to medicines, a nonprofit is sending technology and…
.jpg)
STAT+: Pharmalittle: We’re reading about a boy dying in Pfizer trial; AstraZeneca yanking Covid shot, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case
In the second-largest fine ever levied on a pharmaceutical company, Endo Health Solutions was ordered…
STAT+: Pharmalittle: We’re reading about MDMA for PTSD, a CRISPR treatment for blindness, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Pharmalittle: We’re reading about FTC reviewing Novo-Catalent deal, Amneal opioid settlement, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious…
STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about FTC fighting ‘junk’ patents, Pfizer direct-to-consumer plans, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: ‘Skinny labels’ on generic medicines saved Medicare $15 billion over a recent six-year period
A controversial provision of a federal law designed to speed copycat drugs to market and…
STAT+: FTC issues more warnings to drug companies for ‘junk’ patent listings
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it…
STAT+: Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to…
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs…
STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case
After months of sustained criticism, Vertex Pharmaceuticals reached an agreement to provide a pricey cystic…
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…